ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0255

Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint

Vera Golder1, Rangi Kandane-Rathnayake1, Molla Huq2, Worawit Louthrenoo3, Shue Fen Luo4, Yeong-Jian Wu5, Aisha Lateef6, Sargunan Sockalingam7, Sandra Navarra8, Leonid Zamora9, Laniyati Hamijoyo10, Yasuhiro Katsumata11, Masayoshi Harigai12, Madelynn Chan13, Sean O'Neill14, Fiona Goldblatt15, Chak Sing Lau16, Zhanguo Li17, Alberta Hoi18, Mandana Nikpour19 and Eric Morand20, 1Monash University, Clayton, Victoria, Australia, 2University of Melbourne, Melbourne, Victoria, Australia, 3Maharaj Nakorn Chiangmai, Muang, Thailand, 4Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), 5Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), 6National University Hospital, Singapore, Singapore, 7University of Malaya, Kuala Lumpur, Malaysia, 8University of Santo Tomas, Manila, Philippines, 9University of Santo Thomas, Manila, Philippines, 10University of Padjadjaran, Bandung, Indonesia, 11Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 12Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 13Tan Tock Seng Hospital, Singapore, Singapore, 14Sydney University, Sydney, Australia, 15Royal Adelaide Hospital, Adelaide, Australia, 16Hong Kong University, Hong Kong, Hong Kong, 17Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), 18Monash University, Melbourne, Victoria, Australia, 19The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, 20Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

Meeting: ACR Convergence 2020

Keywords: Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The Lupus Low Disease Activity State (LLDAS) has recently undergone prospective longitudinal validation in a multinational cohort, demonstrating the association of attaining LLDAS with protection from damage accrual and flare, results that have been replicated in numerous other observational cohorts. Domain 1 of the original LLDAS operational definition captured the absence of significant disease activity by requiring SLEDAI-2K <4, the absence of SLEDAI activity in major organs, and also the absence of haemolytic anaemia (HA) and gastrointestinal (GI) activity, manifestations not accounted for in the SLEDAI-2K. The requirement for absence of these infrequent clinical features creates the potential to misclassify patients’ LLDAS status, as there is no formal definition of HA and GI activity. This has in turn limited regulatory approval of LLDAS as a clinical trial endpoint. To determine the requirement for capture of HA and GI activity in the LLDAS definition we performed a sensitivity analysis.  

Methods: We analysed the prospective LLDAS longitudinal validation dataset. To evaluate whether HA and GI activity were captured by the physician global assessment (PGA) criterion of LLDAS, we compared patients with and without HA and GI with respect to median PGA and the proportion of patients with PGA >1. The impact on subsequent damage accrual and flare of time-dependent associations of criterion 1 of the LLDAS definition, with and without inclusion of HA and GI activity, were assessed using Cox regression analysis.

Results: Data on 1,707 patients, with 12,689 visits over 2.2 years were analysed. HA and GI activity were recorded in 28 and 73 visits, respectively. The median PGA, and the proportion of patients with PGA >1, were significantly higher in patients with either HA or GI activity (Table 1). Omitting the requirement for absence of HA and GI activity from criterion 1 of the LLDAS definition had no meaningful impact on the protective association with damage accrual in either visit by visit analysis (SLEDAI≤4 ignoring HA&GI: HR 0.55, 95% CI 0.43,0.70, p< 0.001; original definition: 0.55, 95% CI 0.43,0.71, p< 0.001). A similar lack of effect was observed for cumulative time effects of LLDAS (≥50% of time) on reducing damage accrual, and of LLDAS status on disease flare, when the requirement for absence of HA and GI activity was removed.

Conclusion: In data from a large prospective SLE cohort, the PGA adequately captures HA and GI activity. Removing the requirement for ‘absence of HA and GI activity’ in criterion 1 of the LLDAS definition is without effect on the protective associations of LLDAS attainment. Therefore, the definition of LLDAS does not require specification of HA and GI activity, improving its applicability to datasets where this information is not available and simplifying the use of LLDAS as a clinical trial endpoint. Together with published sensitivity analysis of the SLEDAI-2K and prednisolone dose cut-offs, this completes validation of the LLDAS endpoint.


Disclosure: V. Golder, None; R. Kandane-Rathnayake, None; M. Huq, None; W. Louthrenoo, None; S. Luo, None; Y. Wu, None; A. Lateef, None; S. Sockalingam, None; S. Navarra, Eli Lilly, 5, 8, Astra-Zeneca, 5, 8, Astellas, 8, Janssen, 5, 8, Novartis, 8, Pfizer, 8, Biogen, 2, 5; L. Zamora, None; L. Hamijoyo, None; Y. Katsumata, None; M. Harigai, AbbVie Japan GK, 1, 2, Asahi Kasei Corp., 1, Astellas Pharma Inc., 1, Ayumi Pharmaceutical Co. Ltd., 1, 2, Bristol Myers Squibb Co., Ltd, 1, 2, 3, Chugai Pharmaceutical Co. Ltd., 1, 2, Daiichi-Sankyo, Inc., 1, Eisai Pharmaceutical, 1, 2, Nippon Kayaku Co. Ltd., 1, Mitsubishi Tanabe Pharma Co., 1, Taisho Pharmaceutical Co. Ltd., 1, Takeda Pharmaceutical Co. Ltd., 1, 2, Eli Lilly Japan K.K, 1, Pfizer Japan Inc, 1, AbbVie, 1; M. Chan, None; S. O'Neill, None; F. Goldblatt, None; C. Lau, None; Z. Li, None; A. Hoi, None; M. Nikpour, Actelion, 2, 5, 8, GSK, 2, 5, 8, Boehringer Ingelheim, 5; E. Morand, AstraZeneca, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, GlaxoSmithKline, 2, 5, Janssen, 2, 5, Merck Serono, 2, 5, Neovacs, 5, Sandoz, 5, Novartis, 8, AbbVie, 5, Amgen, 5, Biogen, 5.

To cite this abstract in AMA style:

Golder V, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo S, Wu Y, Lateef A, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau C, Li Z, Hoi A, Nikpour M, Morand E. Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/effect-of-removing-haemolytic-and-gastrointestinal-activity-from-the-operational-definition-of-the-lupus-low-disease-activity-state-implications-for-use-as-a-trial-endpoint/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-removing-haemolytic-and-gastrointestinal-activity-from-the-operational-definition-of-the-lupus-low-disease-activity-state-implications-for-use-as-a-trial-endpoint/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology